^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma

Published date:
11/06/2019
Excerpt:
Co-deletion of CDKN2A and MTAP was frequently detected in ibrutinib-resistant tumors but not in ibrutinib-sensitive tumors.
DOI:
https://doi.org/10.1182/blood-2019-125934